Rand Paul discloses, 16 months later, wife's purchase of stock in company behind COVID-19 treatment


Sixteen months late, Sen. Rand Paul (R-Ky.) on Wednesday filed a disclosure with the Senate revealing that on Feb. 26, 2020, his wife, Kelley, purchased stock in Gilead Sciences, a company that produces an antiviral drug used to treat COVID-19.
Under the STOCK Act, which prohibits members of Congress from using information not available to the public for private profit, the disclosure should have been filed within 45 days of the purchase, The Washington Post reports.
The World Health Organization declared COVID-19 a pandemic on March 11, 2020. That spring, the Justice Department launched investigations into several senators who sold stock shortly before the pandemic declaration, which upended the financial industry and caused markets to crash worldwide. Gilead makes remdesivir, an antiviral developed to treat hepatitis C that was also tested for use against infectious diseases. It was administered as part of former President Donald Trump's treatment last October when he was hospitalized for COVID-19.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The stock purchase and late filing raise questions about whether Paul and his family used information given to lawmakers about the coronavirus and the government's plans to fight it so they could make a profit, Prof. James D. Cox of Duke University told the Post. "The senator ought to have an explanation for the trade and, more importantly, why it took him almost a year and a half to discover it from his wife," he said.
Paul's spokeswoman, Kelsey Cooper, told the Post that the senator did not attend any confidential briefings about COVID-19, and after Kelley Paul's stock purchase, he filled out the proper reporting form. Paul just recently found out that the form was never transmitted, Cooper said, and after conferring with the Senate Ethics Committee, he filed the supplemental report and an annual disclosure on Wednesday. Kelley Paul made the stock purchase two days after a top WHO official said remdesivir "may have real efficacy" in treating COVID-19. According to Cooper, the purchase was between $1,000 and $15,000, and Kelley Paul ended up losing money.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
5 artfully drawn cartoons about Donald Trump's Epstein doodle
Cartoons Artists take on a mountainous legacy, creepy art, and more
-
Violent videos of Charlie Kirk’s death are renewing debate over online censorship
Talking Points Social media ‘promises unfiltered access, but without guarantees of truth and without protection from harm’
-
What led to Poland invoking NATO’s Article 4 and where could it lead?
TODAY'S BIG QUESTION After a Russian drone blitz, Warsaw’s rare move to invoke the important NATO statute has potentially moved Europe closer to continent-wide warfare
-
House posts lewd Epstein note attributed to Trump
Speed Read The estate of Jeffrey Epstein turned over the infamous 2003 birthday note from President Donald Trump
-
Supreme Court allows 'roving' race-tied ICE raids
Speed Read The court paused a federal judge's order barring agents from detaining suspected undocumented immigrants in LA based on race
-
South Korea to fetch workers detained in Georgia raid
Speed Read More than 300 South Korean workers detained in an immigration raid at a Hyundai plant will be released
-
DC sues Trump to end Guard 'occupation'
Speed Read D.C. Attorney General Brian Schwalb argues that the unsolicited military presence violates the law
-
RFK Jr. faces bipartisan heat in Senate hearing
Speed Read The health secretary defended his leadership amid CDC turmoil and deflected questions about the restricted availability of vaccines
-
White House defends boat strike as legal doubts mount
Speed Read Experts say there was no legal justification for killing 11 alleged drug-traffickers
-
Epstein accusers urge full file release, hint at own list
speed read A rally was organized by Reps. Ro Khanna and Thomas Massie, who are hoping to force a vote on their Epstein Files Transparency Act
-
Court hands Harvard a win in Trump funding battle
Speed Read The Trump administration was ordered to restore Harvard's $2 billion in research grants